Global Gynecology Drugs Market

Gynecology Drugs Comprehensive Study by Therapeutics (Hormonal therapy, Non-Hormonal therapy), Prescription Mode (Prescription Based Drugs, OTC Drugs), Indication (Gynecology Cancers, Endometriosis, Female Infertility, Menopausal Disorder, Gynecology Infections, Polycystic Ovary Syndrome, Contraception (Birth Control), Others) Players and Region - Global Market Outlook to 2026

Gynecology Drugs Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 6.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Gynecology Drugs Market Scope
Gynecological diseases are those types of medical conditions which is precise to the female reproductive system. It includes conditions, which affect the ovaries, uterus, and their appendages. It affects both internal and external organs in the female pelvis as well as abdominal areas. Major symptoms of the gynecologic disease are bleeding between periods, itching, burning, swelling, redness, or soreness in the vaginal area, increased vaginal discharge, and discomfort during intercourse and others. Consistent rise in awareness about health with rising demand for better gynecological treatments are some of the major drivers which are propelling the growth of the market.

According to AMA, the Global Gynecology Drugs market is expected to see growth rate of 6.2%

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Gynecology Drugs market throughout the predicted period.

Eli Lilly and Company (United States), Pfizer Inc (United States), Merck & Co., Inc. (United States), Amgen Inc. (United States), AstraZeneca plc (United Kingdom), F. Hoffmann-La Roche AG (Switzerland), Allergan Plc. (Ireland), Bayer AG (Germany), Abbott Laboratories (United States) and AbbVie Inc. (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Gynecology Drugs market and Region with country level break-up.

On the basis of geography, the market of Gynecology Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
On February 2017, the AstraZeneca PLC (United Kingdom) Company has entered the agreement with TerSera Therapeutics LLC (United States) Company for the commercial rights to Zoladex. Zoladex is used to treat prostate cancer, breast cancer, and certain benign gynecological disorders. Hence, this acquisition has helped the company to expand its product portfolio of the company.
On Jan 2017, according to Siemens Healthineers (Germany), health care expenditure in emerging economies increased by 11% from 1995 to 2012, which is anticipated to reach 33% by 2022. This will, in turn, propel the growth of the gynecology drugs market. and On July 2018, the AbbVie Inc. (United States) Company had received FDA Approval of ORILISSA for the Management of Moderate to Severe Pain Associated with Endometriosis. However, endometriosis is one of the most common gynecologic disorders in the United States. This approval will help in strengthening the position of the company in the United States.


Market Trend
  • Technology Advancement of the Gynecological Drugs
  • Convenience of Using Online Pharmacy as well as Rise in Number of Internet Users

Market Drivers
  • Rise in Prevalence of Gynecological Diseases
  • Change in Lifestyle of the Global Female Population

Opportunities
  • Mounting Demand from Emerging Economics Such as India, China and others

Restraints
  • Stringent Regulatory Framework as well as High-Quality Standards Set by Market Leaders

Challenges
  • Problem Related to High Prices of Gynecology Products


Key Target Audience
Manufacturers of Gynecology Drugs, Suppliers of Gynecology Drugs, Wholesalers, Distributors and Retailers of Gynecology Drugs, Research and Development (R&D) Companies, Research Organization, Federal Agencies and Others

Report Objectives / Segmentation Covered

By Therapeutics
  • Hormonal therapy
  • Non-Hormonal therapy

By Prescription Mode
  • Prescription Based Drugs
  • OTC Drugs

By Indication
  • Gynecology Cancers
  • Endometriosis
  • Female Infertility
  • Menopausal Disorder
  • Gynecology Infections
  • Polycystic Ovary Syndrome
  • Contraception (Birth Control)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Prevalence of Gynecological Diseases
      • 3.2.2. Change in Lifestyle of the Global Female Population
    • 3.3. Market Challenges
      • 3.3.1. Problem Related to High Prices of Gynecology Products
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement of the Gynecological Drugs
      • 3.4.2. Convenience of Using Online Pharmacy as well as Rise in Number of Internet Users
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gynecology Drugs, by Therapeutics , Prescription Mode, Indication and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Gynecology Drugs (Value)
      • 5.2.1. Global Gynecology Drugs by: Prescription Mode (Value)
        • 5.2.1.1. Prescription Based Drugs
        • 5.2.1.2. OTC Drugs
      • 5.2.2. Global Gynecology Drugs Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global Gynecology Drugs (Volume)
      • 5.3.1. Global Gynecology Drugs by: Prescription Mode (Volume)
        • 5.3.1.1. Prescription Based Drugs
        • 5.3.1.2. OTC Drugs
      • 5.3.2. Global Gynecology Drugs Region
        • 5.3.2.1. South America
          • 5.3.2.1.1. Brazil
          • 5.3.2.1.2. Argentina
          • 5.3.2.1.3. Rest of South America
        • 5.3.2.2. Asia Pacific
          • 5.3.2.2.1. China
          • 5.3.2.2.2. Japan
          • 5.3.2.2.3. India
          • 5.3.2.2.4. South Korea
          • 5.3.2.2.5. Taiwan
          • 5.3.2.2.6. Australia
          • 5.3.2.2.7. Rest of Asia-Pacific
        • 5.3.2.3. Europe
          • 5.3.2.3.1. Germany
          • 5.3.2.3.2. France
          • 5.3.2.3.3. Italy
          • 5.3.2.3.4. United Kingdom
          • 5.3.2.3.5. Netherlands
          • 5.3.2.3.6. Rest of Europe
        • 5.3.2.4. MEA
          • 5.3.2.4.1. Middle East
          • 5.3.2.4.2. Africa
        • 5.3.2.5. North America
          • 5.3.2.5.1. United States
          • 5.3.2.5.2. Canada
          • 5.3.2.5.3. Mexico
    • 5.4. Global Gynecology Drugs (Price)
  • 6. Gynecology Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Allergan Plc. (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AbbVie Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gynecology Drugs Sale, by Therapeutics , Prescription Mode, Indication and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Gynecology Drugs (Value)
      • 7.2.1. Global Gynecology Drugs by: Prescription Mode (Value)
        • 7.2.1.1. Prescription Based Drugs
        • 7.2.1.2. OTC Drugs
      • 7.2.2. Global Gynecology Drugs Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global Gynecology Drugs (Volume)
      • 7.3.1. Global Gynecology Drugs by: Prescription Mode (Volume)
        • 7.3.1.1. Prescription Based Drugs
        • 7.3.1.2. OTC Drugs
      • 7.3.2. Global Gynecology Drugs Region
        • 7.3.2.1. South America
          • 7.3.2.1.1. Brazil
          • 7.3.2.1.2. Argentina
          • 7.3.2.1.3. Rest of South America
        • 7.3.2.2. Asia Pacific
          • 7.3.2.2.1. China
          • 7.3.2.2.2. Japan
          • 7.3.2.2.3. India
          • 7.3.2.2.4. South Korea
          • 7.3.2.2.5. Taiwan
          • 7.3.2.2.6. Australia
          • 7.3.2.2.7. Rest of Asia-Pacific
        • 7.3.2.3. Europe
          • 7.3.2.3.1. Germany
          • 7.3.2.3.2. France
          • 7.3.2.3.3. Italy
          • 7.3.2.3.4. United Kingdom
          • 7.3.2.3.5. Netherlands
          • 7.3.2.3.6. Rest of Europe
        • 7.3.2.4. MEA
          • 7.3.2.4.1. Middle East
          • 7.3.2.4.2. Africa
        • 7.3.2.5. North America
          • 7.3.2.5.1. United States
          • 7.3.2.5.2. Canada
          • 7.3.2.5.3. Mexico
    • 7.4. Global Gynecology Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gynecology Drugs: by Prescription Mode(USD Million)
  • Table 2. Gynecology Drugs Prescription Based Drugs , by Region USD Million (2015-2020)
  • Table 3. Gynecology Drugs OTC Drugs , by Region USD Million (2015-2020)
  • Table 4. South America Gynecology Drugs, by Country USD Million (2015-2020)
  • Table 5. South America Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 6. South America Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 7. South America Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 8. Brazil Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 9. Brazil Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 10. Brazil Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 11. Argentina Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 12. Argentina Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 13. Argentina Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 14. Rest of South America Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 15. Rest of South America Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 16. Rest of South America Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 17. Asia Pacific Gynecology Drugs, by Country USD Million (2015-2020)
  • Table 18. Asia Pacific Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 19. Asia Pacific Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 20. Asia Pacific Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 21. China Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 22. China Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 23. China Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 24. Japan Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 25. Japan Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 26. Japan Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 27. India Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 28. India Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 29. India Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 30. South Korea Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 31. South Korea Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 32. South Korea Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 33. Taiwan Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 34. Taiwan Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 35. Taiwan Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 36. Australia Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 37. Australia Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 38. Australia Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 39. Rest of Asia-Pacific Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 40. Rest of Asia-Pacific Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 41. Rest of Asia-Pacific Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 42. Europe Gynecology Drugs, by Country USD Million (2015-2020)
  • Table 43. Europe Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 44. Europe Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 45. Europe Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 46. Germany Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 47. Germany Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 48. Germany Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 49. France Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 50. France Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 51. France Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 52. Italy Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 53. Italy Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 54. Italy Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 55. United Kingdom Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 56. United Kingdom Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 57. United Kingdom Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 58. Netherlands Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 59. Netherlands Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 60. Netherlands Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 61. Rest of Europe Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 62. Rest of Europe Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 63. Rest of Europe Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 64. MEA Gynecology Drugs, by Country USD Million (2015-2020)
  • Table 65. MEA Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 66. MEA Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 67. MEA Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 68. Middle East Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 69. Middle East Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 70. Middle East Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 71. Africa Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 72. Africa Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 73. Africa Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 74. North America Gynecology Drugs, by Country USD Million (2015-2020)
  • Table 75. North America Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 76. North America Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 77. North America Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 78. United States Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 79. United States Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 80. United States Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 81. Canada Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 82. Canada Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 83. Canada Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 84. Mexico Gynecology Drugs, by Therapeutics USD Million (2015-2020)
  • Table 85. Mexico Gynecology Drugs, by Prescription Mode USD Million (2015-2020)
  • Table 86. Mexico Gynecology Drugs, by Indication USD Million (2015-2020)
  • Table 87. Gynecology Drugs Sales: by Prescription Mode(M Tons)
  • Table 88. Gynecology Drugs Sales Prescription Based Drugs , by Region M Tons (2015-2020)
  • Table 89. Gynecology Drugs Sales OTC Drugs , by Region M Tons (2015-2020)
  • Table 90. South America Gynecology Drugs Sales, by Country M Tons (2015-2020)
  • Table 91. South America Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 92. South America Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 93. South America Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 94. Brazil Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 95. Brazil Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 96. Brazil Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 97. Argentina Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 98. Argentina Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 99. Argentina Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 100. Rest of South America Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 101. Rest of South America Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 102. Rest of South America Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 103. Asia Pacific Gynecology Drugs Sales, by Country M Tons (2015-2020)
  • Table 104. Asia Pacific Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 105. Asia Pacific Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 106. Asia Pacific Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 107. China Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 108. China Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 109. China Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 110. Japan Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 111. Japan Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 112. Japan Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 113. India Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 114. India Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 115. India Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 116. South Korea Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 117. South Korea Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 118. South Korea Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 119. Taiwan Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 120. Taiwan Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 121. Taiwan Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 122. Australia Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 123. Australia Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 124. Australia Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 125. Rest of Asia-Pacific Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 126. Rest of Asia-Pacific Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 127. Rest of Asia-Pacific Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 128. Europe Gynecology Drugs Sales, by Country M Tons (2015-2020)
  • Table 129. Europe Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 130. Europe Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 131. Europe Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 132. Germany Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 133. Germany Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 134. Germany Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 135. France Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 136. France Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 137. France Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 138. Italy Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 139. Italy Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 140. Italy Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 141. United Kingdom Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 142. United Kingdom Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 143. United Kingdom Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 144. Netherlands Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 145. Netherlands Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 146. Netherlands Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 147. Rest of Europe Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 148. Rest of Europe Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 149. Rest of Europe Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 150. MEA Gynecology Drugs Sales, by Country M Tons (2015-2020)
  • Table 151. MEA Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 152. MEA Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 153. MEA Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 154. Middle East Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 155. Middle East Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 156. Middle East Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 157. Africa Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 158. Africa Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 159. Africa Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 160. North America Gynecology Drugs Sales, by Country M Tons (2015-2020)
  • Table 161. North America Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 162. North America Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 163. North America Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 164. United States Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 165. United States Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 166. United States Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 167. Canada Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 168. Canada Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 169. Canada Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 170. Mexico Gynecology Drugs Sales, by Therapeutics M Tons (2015-2020)
  • Table 171. Mexico Gynecology Drugs Sales, by Prescription Mode M Tons (2015-2020)
  • Table 172. Mexico Gynecology Drugs Sales, by Indication M Tons (2015-2020)
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Company Basic Information, Sales Area and Its Competitors
  • Table 178. Company Basic Information, Sales Area and Its Competitors
  • Table 179. Company Basic Information, Sales Area and Its Competitors
  • Table 180. Company Basic Information, Sales Area and Its Competitors
  • Table 181. Company Basic Information, Sales Area and Its Competitors
  • Table 182. Company Basic Information, Sales Area and Its Competitors
  • Table 183. Gynecology Drugs: by Prescription Mode(USD Million)
  • Table 184. Gynecology Drugs Prescription Based Drugs , by Region USD Million (2021-2026)
  • Table 185. Gynecology Drugs OTC Drugs , by Region USD Million (2021-2026)
  • Table 186. South America Gynecology Drugs, by Country USD Million (2021-2026)
  • Table 187. South America Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 188. South America Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 189. South America Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 190. Brazil Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 191. Brazil Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 192. Brazil Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 193. Argentina Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 194. Argentina Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 195. Argentina Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 196. Rest of South America Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 197. Rest of South America Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 198. Rest of South America Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 199. Asia Pacific Gynecology Drugs, by Country USD Million (2021-2026)
  • Table 200. Asia Pacific Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 201. Asia Pacific Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 202. Asia Pacific Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 203. China Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 204. China Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 205. China Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 206. Japan Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 207. Japan Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 208. Japan Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 209. India Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 210. India Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 211. India Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 212. South Korea Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 213. South Korea Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 214. South Korea Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 215. Taiwan Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 216. Taiwan Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 217. Taiwan Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 218. Australia Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 219. Australia Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 220. Australia Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 221. Rest of Asia-Pacific Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 222. Rest of Asia-Pacific Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 223. Rest of Asia-Pacific Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 224. Europe Gynecology Drugs, by Country USD Million (2021-2026)
  • Table 225. Europe Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 226. Europe Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 227. Europe Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 228. Germany Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 229. Germany Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 230. Germany Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 231. France Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 232. France Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 233. France Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 234. Italy Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 235. Italy Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 236. Italy Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 237. United Kingdom Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 238. United Kingdom Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 239. United Kingdom Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 240. Netherlands Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 241. Netherlands Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 242. Netherlands Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 243. Rest of Europe Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 244. Rest of Europe Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 245. Rest of Europe Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 246. MEA Gynecology Drugs, by Country USD Million (2021-2026)
  • Table 247. MEA Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 248. MEA Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 249. MEA Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 250. Middle East Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 251. Middle East Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 252. Middle East Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 253. Africa Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 254. Africa Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 255. Africa Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 256. North America Gynecology Drugs, by Country USD Million (2021-2026)
  • Table 257. North America Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 258. North America Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 259. North America Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 260. United States Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 261. United States Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 262. United States Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 263. Canada Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 264. Canada Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 265. Canada Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 266. Mexico Gynecology Drugs, by Therapeutics USD Million (2021-2026)
  • Table 267. Mexico Gynecology Drugs, by Prescription Mode USD Million (2021-2026)
  • Table 268. Mexico Gynecology Drugs, by Indication USD Million (2021-2026)
  • Table 269. Gynecology Drugs Sales: by Prescription Mode(M Tons)
  • Table 270. Gynecology Drugs Sales Prescription Based Drugs , by Region M Tons (2021-2026)
  • Table 271. Gynecology Drugs Sales OTC Drugs , by Region M Tons (2021-2026)
  • Table 272. South America Gynecology Drugs Sales, by Country M Tons (2021-2026)
  • Table 273. South America Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 274. South America Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 275. South America Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 276. Brazil Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 277. Brazil Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 278. Brazil Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 279. Argentina Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 280. Argentina Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 281. Argentina Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 282. Rest of South America Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 283. Rest of South America Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 284. Rest of South America Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 285. Asia Pacific Gynecology Drugs Sales, by Country M Tons (2021-2026)
  • Table 286. Asia Pacific Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 287. Asia Pacific Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 288. Asia Pacific Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 289. China Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 290. China Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 291. China Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 292. Japan Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 293. Japan Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 294. Japan Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 295. India Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 296. India Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 297. India Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 298. South Korea Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 299. South Korea Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 300. South Korea Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 301. Taiwan Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 302. Taiwan Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 303. Taiwan Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 304. Australia Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 305. Australia Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 306. Australia Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 307. Rest of Asia-Pacific Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 308. Rest of Asia-Pacific Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 309. Rest of Asia-Pacific Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 310. Europe Gynecology Drugs Sales, by Country M Tons (2021-2026)
  • Table 311. Europe Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 312. Europe Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 313. Europe Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 314. Germany Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 315. Germany Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 316. Germany Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 317. France Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 318. France Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 319. France Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 320. Italy Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 321. Italy Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 322. Italy Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 323. United Kingdom Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 324. United Kingdom Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 325. United Kingdom Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 326. Netherlands Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 327. Netherlands Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 328. Netherlands Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 329. Rest of Europe Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 330. Rest of Europe Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 331. Rest of Europe Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 332. MEA Gynecology Drugs Sales, by Country M Tons (2021-2026)
  • Table 333. MEA Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 334. MEA Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 335. MEA Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 336. Middle East Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 337. Middle East Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 338. Middle East Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 339. Africa Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 340. Africa Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 341. Africa Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 342. North America Gynecology Drugs Sales, by Country M Tons (2021-2026)
  • Table 343. North America Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 344. North America Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 345. North America Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 346. United States Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 347. United States Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 348. United States Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 349. Canada Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 350. Canada Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 351. Canada Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 352. Mexico Gynecology Drugs Sales, by Therapeutics M Tons (2021-2026)
  • Table 353. Mexico Gynecology Drugs Sales, by Prescription Mode M Tons (2021-2026)
  • Table 354. Mexico Gynecology Drugs Sales, by Indication M Tons (2021-2026)
  • Table 355. Research Programs/Design for This Report
  • Table 356. Key Data Information from Secondary Sources
  • Table 357. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gynecology Drugs: by Prescription Mode USD Million (2015-2020)
  • Figure 5. South America Gynecology Drugs Share (%), by Country
  • Figure 6. Asia Pacific Gynecology Drugs Share (%), by Country
  • Figure 7. Europe Gynecology Drugs Share (%), by Country
  • Figure 8. MEA Gynecology Drugs Share (%), by Country
  • Figure 9. North America Gynecology Drugs Share (%), by Country
  • Figure 10. Global Gynecology Drugs: by Prescription Mode M Tons (2015-2020)
  • Figure 11. South America Gynecology Drugs Share (%), by Country
  • Figure 12. Asia Pacific Gynecology Drugs Share (%), by Country
  • Figure 13. Europe Gynecology Drugs Share (%), by Country
  • Figure 14. MEA Gynecology Drugs Share (%), by Country
  • Figure 15. North America Gynecology Drugs Share (%), by Country
  • Figure 16. Global Gynecology Drugs share by Players 2020 (%)
  • Figure 17. Global Gynecology Drugs share by Players (Top 3) 2020(%)
  • Figure 18. Global Gynecology Drugs share by Players (Top 5) 2020(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 22. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 24. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 28. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 30. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 32. Allergan Plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 33. Allergan Plc. (Ireland) Revenue: by Geography 2020
  • Figure 34. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 36. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 37. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 38. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 40. Global Gynecology Drugs: by Prescription Mode USD Million (2021-2026)
  • Figure 41. South America Gynecology Drugs Share (%), by Country
  • Figure 42. Asia Pacific Gynecology Drugs Share (%), by Country
  • Figure 43. Europe Gynecology Drugs Share (%), by Country
  • Figure 44. MEA Gynecology Drugs Share (%), by Country
  • Figure 45. North America Gynecology Drugs Share (%), by Country
  • Figure 46. Global Gynecology Drugs: by Prescription Mode M Tons (2021-2026)
  • Figure 47. South America Gynecology Drugs Share (%), by Country
  • Figure 48. Asia Pacific Gynecology Drugs Share (%), by Country
  • Figure 49. Europe Gynecology Drugs Share (%), by Country
  • Figure 50. MEA Gynecology Drugs Share (%), by Country
  • Figure 51. North America Gynecology Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Eli Lilly and Company (United States)
  • Pfizer Inc (United States)
  • Merck & Co., Inc. (United States)
  • Amgen Inc. (United States)
  • AstraZeneca plc (United Kingdom)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Allergan Plc. (Ireland)
  • Bayer AG (Germany)
  • Abbott Laboratories (United States)
  • AbbVie Inc. (United States)
Select User Access Type

Key Highlights of Report


Aug 2021 248 Pages 95 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gynecology Drugs Market Quantitative research analysis
Global Gynecology Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Gynecology Drugs study can be customized to meet your requirements. The market size breakdown by type [], by end use application [].
The Gynecology Drugs Market is gaining popularity and expected to see strong valuation by 2026.
According to AMA, the Global Gynecology Drugs market is expected to see growth rate of 6.2%.

Know More About Global Gynecology Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Cough Suppressant Drugs Comprehensive Study by Type (Antitussives, Expectorants), Application (Healing of cough, Remedy for Flu), End-User (Hospitals, Diagnostic Clinics, Online Pharmacy, Retail Phar...
$ 3350
Cytotoxic Drug Comprehensive Study by Application (Breast Cancer, Blood Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other), Dosage (Injection, Solid Oral, Others) Players and Region - Global Ma...
$ 3500
Pharma & Cosmetics Comprehensive Study by Distribution Channel (Supermarket, Onlien Stores, Cosmetics Stores, Drug Stores), Cosmetics (Skincare, Haircare, Oral Care, Others), Pharmaceutical (Tablets,...
$ 3450
Contrast Agents Comprehensive Study by Type (Iodine-based, Barium-Sulfate, Gadolinium), Application (Interventional Radiology, Interventional Cardiology), Route of Administration (Intravenously/intra...
$ 3750
Skin Adhesives Comprehensive Study by Application (Ophthalmic Surgery, ENT Surgery, Dental Surgery, General Surgery, Plastic Surgery, Gynaecology, Gastroenterology, Orthopaedic, Surgical oncology, Ot...
$ 3650
Left Ventricular Dysfunction Drug Comprehensive Study by Type (BAY-1142524, CAP-1002, Carvedilol CR, CTX-101, Omecamtiv Mecarbil, Others), Application (Hospital, Clinic, Others), Drug Type (Prescript...
$ 3450